Arcturus Therapeutics Holdings, Inc. (ARCT)

Arcturus announced its Q2 2025 financial update, reporting decreased revenue due to reduced contributions from its collaboration with CSL. Arcturus shares plunged after interim Phase 2 data for ARCT-032 failed to show meaningful improvements in lung function. The company faced an investigation into potential violations of federal securities laws due to allegations of providing potentially misleading business information to investors. Canaccord Genuity maintained a "Buy" rating on Arcturus Therapeutics and increased its price target following the company's Q3 2024 earnings report. ARCT shares had plummeted due to the mixed interim results for ARCT-032. Wall Street Zen lowered its rating on Arcturus Therapeutics from "hold" to "sell." Citigroup cut its price target on Arcturus Therapeutics and set a "neutral" rating. ARCT's share price passed below its two hundred day moving average.

Information regarding specific demand seasonality for Arcturus Therapeutics Holdings, Inc.'s products and services is not readily available through public searches and often requires access to specialized financial data platforms.

Arcturus Therapeutics is a biotechnology company focused on developing mRNA medicines and vaccines for infectious diseases and rare liver and respiratory conditions, leveraging its LUNAR® and STARR® technology platforms. Its product pipeline includes KOSTAIVE (ARCT-154), an approved COVID-19 vaccine; ARCT-810 (LUNAR-OTC) for ornithine transcarbamylase deficiency in Phase 2 trials; ARCT-032 (LUNAR-CF) for cystic fibrosis in Phase 2 trials; ARCT-2138 (LUNAR-FLU), a seasonal influenza vaccine candidate in Phase 1 trials; ARCT-2304 (LUNAR-H5N1), a pandemic influenza vaccine candidate in Phase 1 trials; and ARCT-2301 and ARCT-2303, COVID-19 vaccine candidates in Phase 3 trials. KOSTAIVE has been approved in Japan and the European Union and demonstrated superior immunogenicity compared to conventional mRNA vaccines in a Phase 3 study. Positive Phase 2 biomarker results have been observed for ARCT-810, with Phase 3 discussions anticipated in the first half of 2026. Interim Phase 2 data for ARCT-032 was expected in September 2025, with full enrollment by year-end 2025 and Phase 3 discussions in 2026. ARCT-2138 showed encouraging Phase 1 data in June 2025 and is expected to enter larger trials in late 2025/2026. Results for ARCT-2304 are expected in Q4 2025, and this program has U.S. FDA Fast Track status and government funding.

Arcturus Therapeutics is headquartered in San Diego, California, USA, and has employees across four continents, including North America, Europe, and Asia. The company also has a joint venture in Japan called ARCALIS, which focuses on the manufacturing of mRNA vaccines and therapeutics.

Arcturus Therapeutics has generally maintained a positive brand reputation due to its involvement in addressing unmet medical needs and its contributions to public health, particularly through its mRNA-based COVID-19 vaccine candidate. However, the company's reputation was likely impacted by an investigation into potential violations of federal securities laws involving Arcturus Therapeutics Holdings Inc., stemming from allegations of providing potentially misleading business information to the investing public.

Arcturus Therapeutics has significant institutional ownership, with 277 institutional owners and shareholders holding a total of 29,917,893 shares. Major institutional owners include Federated Hermes, Inc., BlackRock, Inc., Vanguard Group Inc., Sumitomo Mitsui Trust Holdings, Inc., Nikko Asset Management Americas, Inc., ARK Investment Management LLC, and Balyasny Asset Management Llc. Joseph Payne, the company's President, CEO, and Director, is also a significant individual owner.